| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Kidney Injury | 9 | 2023 | 339 | 1.260 |
Why?
|
| Kidney | 9 | 2021 | 1093 | 1.030 |
Why?
|
| Hypertension | 2 | 2019 | 748 | 0.790 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2013 | 688 | 0.790 |
Why?
|
| Endotoxemia | 3 | 2012 | 18 | 0.770 |
Why?
|
| Kidney Glomerulus | 6 | 2013 | 121 | 0.620 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2019 | 20 | 0.610 |
Why?
|
| Apolipoprotein L1 | 1 | 2019 | 7 | 0.610 |
Why?
|
| Tetrazoles | 1 | 2019 | 21 | 0.600 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 44 | 0.600 |
Why?
|
| Complement Activation | 6 | 2015 | 84 | 0.590 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2019 | 151 | 0.570 |
Why?
|
| Benzimidazoles | 1 | 2019 | 112 | 0.570 |
Why?
|
| RNA, Small Interfering | 2 | 2019 | 556 | 0.550 |
Why?
|
| Kidney Transplantation | 6 | 2024 | 871 | 0.530 |
Why?
|
| Colistin | 2 | 2017 | 7 | 0.530 |
Why?
|
| Lipopolysaccharides | 7 | 2013 | 300 | 0.520 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 256 | 0.500 |
Why?
|
| Pharmacogenetics | 2 | 2019 | 456 | 0.460 |
Why?
|
| Nephritis | 2 | 2018 | 17 | 0.430 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2013 | 68 | 0.390 |
Why?
|
| Urothelium | 1 | 2013 | 67 | 0.380 |
Why?
|
| Mice, Inbred C57BL | 12 | 2013 | 3431 | 0.380 |
Why?
|
| Tight Junction Proteins | 1 | 2012 | 14 | 0.370 |
Why?
|
| Sepsis | 3 | 2013 | 382 | 0.370 |
Why?
|
| Tight Junctions | 2 | 2015 | 154 | 0.360 |
Why?
|
| Endothelial Cells | 3 | 2015 | 477 | 0.350 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2009 | 76 | 0.330 |
Why?
|
| Mice | 20 | 2021 | 12230 | 0.300 |
Why?
|
| Graft Rejection | 3 | 2021 | 1123 | 0.300 |
Why?
|
| Caspase 8 | 1 | 2009 | 32 | 0.300 |
Why?
|
| Myosin-Light-Chain Kinase | 1 | 2009 | 38 | 0.290 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2009 | 57 | 0.290 |
Why?
|
| Immunosuppressive Agents | 2 | 2024 | 987 | 0.250 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2019 | 2484 | 0.240 |
Why?
|
| Animals | 23 | 2021 | 27973 | 0.240 |
Why?
|
| Receptors, Cell Surface | 2 | 2004 | 291 | 0.220 |
Why?
|
| Kidney Tubules | 3 | 2013 | 91 | 0.220 |
Why?
|
| Complement C5a | 2 | 2015 | 24 | 0.220 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2005 | 23 | 0.220 |
Why?
|
| Caspases | 1 | 2004 | 151 | 0.210 |
Why?
|
| Membrane Glycoproteins | 2 | 2004 | 443 | 0.210 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 3 | 2013 | 40 | 0.210 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2024 | 36 | 0.210 |
Why?
|
| Apoptosis | 6 | 2009 | 1719 | 0.200 |
Why?
|
| Complement C3 | 4 | 2002 | 58 | 0.190 |
Why?
|
| Allografts | 2 | 2021 | 205 | 0.190 |
Why?
|
| Tacrolimus | 2 | 2024 | 372 | 0.180 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2002 | 84 | 0.180 |
Why?
|
| Male | 16 | 2024 | 44355 | 0.170 |
Why?
|
| Disease Models, Animal | 5 | 2014 | 2479 | 0.170 |
Why?
|
| Receptors, Complement | 4 | 2002 | 46 | 0.170 |
Why?
|
| Recurrence | 1 | 2024 | 1188 | 0.170 |
Why?
|
| Glomerulonephritis | 1 | 2001 | 80 | 0.160 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2000 | 23 | 0.160 |
Why?
|
| Antigens, CD | 1 | 2002 | 476 | 0.160 |
Why?
|
| Thrombosis | 1 | 2023 | 308 | 0.160 |
Why?
|
| Biological Variation, Individual | 1 | 2019 | 7 | 0.150 |
Why?
|
| Gene Targeting | 1 | 2019 | 72 | 0.150 |
Why?
|
| Blood-Brain Barrier | 3 | 2015 | 79 | 0.150 |
Why?
|
| Biphenyl Compounds | 1 | 2019 | 60 | 0.150 |
Why?
|
| Pharmacogenomic Variants | 1 | 2019 | 45 | 0.150 |
Why?
|
| Fatal Outcome | 1 | 2019 | 292 | 0.150 |
Why?
|
| Drug Monitoring | 1 | 2019 | 119 | 0.140 |
Why?
|
| Calcium Channel Blockers | 1 | 2019 | 118 | 0.140 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2019 | 108 | 0.140 |
Why?
|
| Signal Transduction | 1 | 2009 | 3497 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 1000 | 0.140 |
Why?
|
| Albuminuria | 2 | 2013 | 51 | 0.140 |
Why?
|
| Drug Delivery Systems | 1 | 2019 | 191 | 0.140 |
Why?
|
| Bowman Capsule | 1 | 2018 | 6 | 0.140 |
Why?
|
| Chronic Disease | 2 | 2019 | 941 | 0.140 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 1517 | 0.140 |
Why?
|
| Gene Expression Regulation | 3 | 2021 | 1980 | 0.130 |
Why?
|
| Kidney Failure, Chronic | 2 | 2024 | 430 | 0.130 |
Why?
|
| Immunoglobulin G | 5 | 2021 | 465 | 0.130 |
Why?
|
| B-Lymphocytes | 2 | 2021 | 703 | 0.130 |
Why?
|
| Complement Inactivator Proteins | 3 | 2002 | 27 | 0.130 |
Why?
|
| Renal Dialysis | 2 | 2018 | 349 | 0.130 |
Why?
|
| Immunity, Cellular | 1 | 2018 | 183 | 0.130 |
Why?
|
| Cysteine Proteinase Inhibitors | 2 | 2009 | 52 | 0.130 |
Why?
|
| Neutrophil Infiltration | 2 | 2009 | 32 | 0.120 |
Why?
|
| Mice, Knockout | 5 | 2013 | 2121 | 0.120 |
Why?
|
| Income | 1 | 2017 | 86 | 0.120 |
Why?
|
| Genome-Wide Association Study | 3 | 2019 | 1763 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 891 | 0.120 |
Why?
|
| Neutrophils | 4 | 2007 | 324 | 0.120 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2015 | 235 | 0.120 |
Why?
|
| Minority Groups | 1 | 2017 | 149 | 0.120 |
Why?
|
| Enzyme Activation | 2 | 2009 | 672 | 0.120 |
Why?
|
| Receptor, Anaphylatoxin C5a | 1 | 2015 | 21 | 0.110 |
Why?
|
| T-Lymphocytes | 2 | 2018 | 1276 | 0.110 |
Why?
|
| Inflammation | 1 | 2021 | 1049 | 0.110 |
Why?
|
| Humans | 13 | 2024 | 93132 | 0.110 |
Why?
|
| Blood Pressure | 1 | 2019 | 887 | 0.110 |
Why?
|
| Genotype | 1 | 2019 | 1866 | 0.110 |
Why?
|
| Homeodomain Proteins | 2 | 2017 | 556 | 0.110 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2015 | 79 | 0.100 |
Why?
|
| Repressor Proteins | 1 | 2017 | 443 | 0.100 |
Why?
|
| Communication | 1 | 2017 | 433 | 0.100 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2013 | 67 | 0.100 |
Why?
|
| Galectin 3 | 1 | 2013 | 20 | 0.100 |
Why?
|
| Cells, Cultured | 4 | 2015 | 2827 | 0.100 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2013 | 121 | 0.100 |
Why?
|
| Brain | 3 | 2015 | 2337 | 0.100 |
Why?
|
| Adenine Nucleotides | 1 | 2013 | 57 | 0.100 |
Why?
|
| Arabinonucleosides | 1 | 2013 | 37 | 0.100 |
Why?
|
| Necrosis | 1 | 2013 | 203 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2024 | 9070 | 0.100 |
Why?
|
| Female | 7 | 2024 | 48542 | 0.090 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 480 | 0.090 |
Why?
|
| Genes | 1 | 2013 | 256 | 0.090 |
Why?
|
| Cytosine | 1 | 2013 | 121 | 0.090 |
Why?
|
| Kidney Tubules, Distal | 1 | 2012 | 19 | 0.090 |
Why?
|
| Cluster Analysis | 1 | 2013 | 391 | 0.090 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 561 | 0.090 |
Why?
|
| Transcription Factor RelA | 2 | 2009 | 39 | 0.090 |
Why?
|
| Body Weight | 1 | 2013 | 449 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 833 | 0.090 |
Why?
|
| Acute Disease | 1 | 2012 | 838 | 0.080 |
Why?
|
| Reperfusion Injury | 2 | 2002 | 148 | 0.080 |
Why?
|
| Adult | 5 | 2024 | 27849 | 0.080 |
Why?
|
| NF-kappa B | 2 | 2015 | 408 | 0.080 |
Why?
|
| Cell Line | 4 | 2017 | 2458 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2014 | 581 | 0.080 |
Why?
|
| Mice, Transgenic | 4 | 2007 | 1581 | 0.070 |
Why?
|
| Myosin Light Chains | 1 | 2009 | 25 | 0.070 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2009 | 38 | 0.070 |
Why?
|
| Caspase Inhibitors | 1 | 2009 | 32 | 0.070 |
Why?
|
| I-kappa B Proteins | 1 | 2009 | 47 | 0.070 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2009 | 58 | 0.070 |
Why?
|
| Receptors, Complement 3b | 4 | 2002 | 39 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2017 | 1687 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 2301 | 0.070 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 555 | 0.070 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2009 | 87 | 0.070 |
Why?
|
| Middle Aged | 4 | 2024 | 27535 | 0.070 |
Why?
|
| Graft Survival | 2 | 2024 | 939 | 0.070 |
Why?
|
| Clusterin | 1 | 2007 | 13 | 0.070 |
Why?
|
| bcl-X Protein | 1 | 2007 | 54 | 0.070 |
Why?
|
| Cell Adhesion | 1 | 2009 | 416 | 0.070 |
Why?
|
| Brain Diseases, Metabolic | 1 | 2007 | 8 | 0.070 |
Why?
|
| CD18 Antigens | 1 | 2007 | 22 | 0.070 |
Why?
|
| Endotoxins | 1 | 2007 | 36 | 0.070 |
Why?
|
| Aged | 3 | 2019 | 20395 | 0.070 |
Why?
|
| Kidney Diseases | 2 | 2007 | 309 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 2705 | 0.060 |
Why?
|
| Encephalitis | 1 | 2007 | 46 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2007 | 89 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2009 | 1129 | 0.060 |
Why?
|
| Gene Expression | 3 | 2013 | 1304 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2009 | 603 | 0.050 |
Why?
|
| Complement System Proteins | 2 | 2002 | 86 | 0.050 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2004 | 25 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2005 | 204 | 0.050 |
Why?
|
| Injections, Intraperitoneal | 1 | 2004 | 102 | 0.050 |
Why?
|
| Cell Movement | 1 | 2007 | 804 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2024 | 173 | 0.050 |
Why?
|
| Rats | 4 | 2002 | 4028 | 0.050 |
Why?
|
| Mice, Inbred C3H | 1 | 2004 | 368 | 0.050 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2004 | 91 | 0.050 |
Why?
|
| Autoantibodies | 2 | 2021 | 276 | 0.050 |
Why?
|
| Toll-Like Receptors | 1 | 2004 | 102 | 0.050 |
Why?
|
| Glomerular Mesangium | 1 | 2002 | 21 | 0.050 |
Why?
|
| Endothelium, Vascular | 2 | 2002 | 436 | 0.050 |
Why?
|
| CD55 Antigens | 1 | 2002 | 21 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2024 | 289 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2002 | 20 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2024 | 753 | 0.050 |
Why?
|
| Species Specificity | 1 | 2004 | 683 | 0.050 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2002 | 20 | 0.050 |
Why?
|
| Nitric Oxide Synthase | 1 | 2002 | 123 | 0.040 |
Why?
|
| Complement C5b | 1 | 2001 | 2 | 0.040 |
Why?
|
| Heymann Nephritis Antigenic Complex | 1 | 2001 | 3 | 0.040 |
Why?
|
| Complement C3b | 1 | 2001 | 5 | 0.040 |
Why?
|
| Complement C3d | 1 | 2001 | 6 | 0.040 |
Why?
|
| Transgenes | 1 | 2002 | 171 | 0.040 |
Why?
|
| CD59 Antigens | 1 | 2001 | 17 | 0.040 |
Why?
|
| Complement C5 | 1 | 2001 | 14 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2001 | 68 | 0.040 |
Why?
|
| Palatine Tonsil | 1 | 2021 | 31 | 0.040 |
Why?
|
| Gene Ontology | 1 | 2021 | 37 | 0.040 |
Why?
|
| Renal Circulation | 1 | 2001 | 30 | 0.040 |
Why?
|
| Antigens, Surface | 1 | 2001 | 97 | 0.040 |
Why?
|
| Astrocytes | 2 | 2015 | 136 | 0.040 |
Why?
|
| Lupus Nephritis | 1 | 2002 | 78 | 0.040 |
Why?
|
| Complement Factor H | 1 | 2001 | 34 | 0.040 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2021 | 171 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2001 | 149 | 0.040 |
Why?
|
| Receptors, Immunologic | 1 | 2001 | 139 | 0.040 |
Why?
|
| Time Factors | 1 | 2009 | 5380 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2004 | 463 | 0.040 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2021 | 207 | 0.040 |
Why?
|
| Ischemia | 1 | 2001 | 252 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 81 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 200 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2021 | 1014 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2000 | 550 | 0.040 |
Why?
|
| Risk Factors | 2 | 2019 | 5900 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2017 | 231 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2002 | 1385 | 0.030 |
Why?
|
| Junctional Adhesion Molecules | 1 | 2015 | 3 | 0.030 |
Why?
|
| Claudin-5 | 1 | 2015 | 7 | 0.030 |
Why?
|
| Poverty | 1 | 2017 | 192 | 0.030 |
Why?
|
| United States | 2 | 2019 | 7581 | 0.030 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2015 | 64 | 0.030 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2015 | 70 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2015 | 123 | 0.030 |
Why?
|
| Electric Impedance | 1 | 2015 | 115 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 373 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2017 | 404 | 0.030 |
Why?
|
| Permeability | 1 | 2014 | 143 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 627 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1172 | 0.030 |
Why?
|
| Protein Transport | 1 | 2015 | 438 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 1529 | 0.020 |
Why?
|
| Actin Cytoskeleton | 1 | 2015 | 196 | 0.020 |
Why?
|
| Adolescent | 2 | 2017 | 9550 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 1703 | 0.020 |
Why?
|
| Chicago | 1 | 2018 | 1452 | 0.020 |
Why?
|
| HapMap Project | 1 | 2013 | 47 | 0.020 |
Why?
|
| Comorbidity | 1 | 2017 | 1003 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2017 | 630 | 0.020 |
Why?
|
| Thiazides | 1 | 2012 | 16 | 0.020 |
Why?
|
| Sodium Chloride Symporters | 1 | 2012 | 14 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 3814 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2013 | 201 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2013 | 478 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 304 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 496 | 0.020 |
Why?
|
| Models, Animal | 1 | 2012 | 280 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 696 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 2757 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 3044 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2013 | 660 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2002 | 1236 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 2787 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2023 | 10128 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2013 | 740 | 0.020 |
Why?
|
| Quality of Life | 1 | 2017 | 1776 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2007 | 2020 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 4546 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2007 | 27 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2007 | 54 | 0.020 |
Why?
|
| I-kappa B Kinase | 1 | 2007 | 41 | 0.020 |
Why?
|
| Serum Albumin, Bovine | 1 | 2007 | 47 | 0.020 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2007 | 44 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2007 | 66 | 0.020 |
Why?
|
| Aquaporin 4 | 1 | 2007 | 9 | 0.020 |
Why?
|
| Gliosis | 1 | 2007 | 32 | 0.020 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2007 | 39 | 0.020 |
Why?
|
| Brain Edema | 1 | 2007 | 54 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2007 | 159 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 2545 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2013 | 1416 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 6922 | 0.010 |
Why?
|
| Child | 1 | 2015 | 7273 | 0.010 |
Why?
|
| Nephrosis | 1 | 2002 | 3 | 0.010 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2002 | 28 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2002 | 67 | 0.010 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 2002 | 7 | 0.010 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2002 | 36 | 0.010 |
Why?
|
| Anemia, Hemolytic | 1 | 2002 | 17 | 0.010 |
Why?
|
| Cell Polarity | 1 | 2002 | 118 | 0.010 |
Why?
|
| Erythrocytes | 1 | 2002 | 235 | 0.010 |
Why?
|
| Receptors, Complement 3d | 1 | 2001 | 14 | 0.010 |
Why?
|
| Antibodies | 1 | 2002 | 346 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2001 | 155 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 402 | 0.010 |
Why?
|
| DNA Primers | 1 | 2001 | 528 | 0.010 |
Why?
|
| Solubility | 1 | 2001 | 186 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 2002 | 255 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2002 | 700 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2002 | 1518 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2001 | 1994 | 0.010 |
Why?
|
| Base Sequence | 1 | 2001 | 2207 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 2889 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 1231 | 0.010 |
Why?
|